Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in philadelphia chromosome-positive leukemias after imatinib resistance or intolerance

Hagop Kantarjian, Phillipp Le Coutre, Jorge Cortes, Javier Pinilla-Ibarz, Arnon Nagler, Andreas Hochhaus, Shinya Kimura, Oliver Ottmann

Research output: Contribution to journalArticle

46 Scopus citations

Fingerprint Dive into the research topics of 'Phase 1 study of INNO-406, a dual Abl/Lyn kinase inhibitor, in philadelphia chromosome-positive leukemias after imatinib resistance or intolerance'. Together they form a unique fingerprint.

Medicine & Life Sciences